Recent studies indicated the prognostic role of AXL in NSCLC suggesting a new additional tool to customized therapy of EGFR treated patients12 and also to the stratification of operable early stage lung adenocarcinoma patients that might benefit from new targeted adjuvant therapy13. The gene discussed is AXL; the disease is non-small cell lung carcinoma.